Greg Slabodkin

The biopharmaceutical industry's funding trends, product pipeline, and pace of R&D spending indicate demand is set to improve this year, say William Blair analysts.

The CDMO has invested in its Le Mans, France site, which it contends is one of the world's leading facilities for antibody-drug conjugate and cytotoxic drug manufacturing.

Faced with the increasing complexity of peptide programs, Japan's drugmakers are turning to outsourcing in preclinical and early stages, contends Neuland Laboratories.

The company's latest capital expenditure on the Juncos site, combined with the $650 million previously announced, is meant to expand its biomanufacturing capabilities.

The additional investment at the drugmaker's Lebanon sites brings its total Indiana capital expansion commitments to more than $21 billion since 2020.

The company plans to exit operations in Idar-Oberstein, Marburg, and Tübingen in Germany by end of 2027, while Singapore operations are expected to conclude in Q1 2027.

The Japanese drugmaker was impacted by contract manufacturing organization obligations and an impairment charge related to its Odawara plant in Japan.

The CDMO is making progress with the production of different GMP batches, while a revenue growth contribution is expected to begin in the second half of 2026.

With Big Pharma's pledge of more than $500 billion to U.S. manufacturing and research, industrial production growth should improve over the next several years, says Newmark.

The company is actively supporting customer reshoring, which is first targeted in its CDMO business and then more broadly in bioproduction and analytical instruments.